- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04505488
Efficacy of the ASPEN Intervention Program in Low-Resource Communities (ASPEN)
May 17, 2022 updated by: Sandra Vanegas, Texas State University, San Marcos
Efficacy of the ASD Screening and Parent ENgagement (ASPEN) Intervention Program in Low-Resource Communities
The ASD Screening and Parent ENgagement (ASPEN) program is a culturally adapted, parent-mediated intervention program.
The ASPEN program is tailored to address social communication and behavioral difficulties that young children with developmental delays may experience in early childhood.
The ASPEN Program includes 12 sessions where parents are provided with psychoeducation about self-care, child development, and evidence-based strategies.
Coaching is also provided to train parents on using evidence-based strategies within the home setting.
The ASPEN program is delivered by a student clinician and a peer leader.
We hypothesize that coaching strategies delivered by the clinician will lead to primary family caregivers learning evidence-based strategies and this will result in improved child outcomes.
We hypothesize that education and family support delivered by peer leaders will help primary family caregivers learn social support strategies and this will lead to improved parent outcomes.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
320
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sandra B Vanegas, PhD
- Phone Number: 5122454579
- Email: svanegas@txstate.edu
Study Contact Backup
- Name: Sandy Magaña, PhD, MSW
- Phone Number: 5122329216
- Email: smagana@austin.utexas.edu
Study Locations
-
-
Texas
-
San Marcos, Texas, United States, 78666
- Recruiting
- Texas State University
-
Contact:
- Sandra B Vanegas, PhD
- Phone Number: 512-245-4579
- Email: svanegas@txstate.edu
-
Principal Investigator:
- Sandra B Vanegas, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 6 years (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Child is between 18 months through 6 years of age
- Child has a medical diagnosis or educational classification of Autism or Autism Spectrum Disorder (ASD) or child is at-risk for Autism/ASD as determined by the Modified-Checklist for Autism in Toddlers - Revised/Follow-up Interview (M-CHAT-R/F) and/or Social Communication Questionnaire (SCQ)
- Child resides in a low-resource household as determined by at least one of the following criteria:
- -Child or family has Medicaid as an insurance provider
- -Child's primary caregiver has achieved a high school or lower education
- -Child resides in a household with an annual income of 200% of the Federal Poverty Level
Exclusion Criteria:
- Primary caregiver does not speak/understand English or Spanish
- Child is younger 18 months or older than 6 years of age
- Child does not have a medical diagnosis or educational classification of Autism/ASD or does not meet at-risk criteria on the M-CHAT-R/F and/or SCQ
- Child does not reside in low-resource household
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Intervention Group
The intervention group will receive a parent manual, a resource packet, and 12 weekly sessions delivered by the clinician and peer leader.
|
The ASPEN intervention is based on naturalistic developmental behavioral intervention strategies to support the development of social communication and play skills and reduce challenging behavior.
Other Names:
|
NO_INTERVENTION: Control Group
The control group will receive a parent manual and a resource packet.
Four phone check-ins will be conducted across 12-14 weeks to address questions by the research team.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adaptive Behavior
Time Frame: Baseline to Post-Intervention (12-14 weeks post baseline) Change
|
Vineland Adaptive Behavior Scales - 3: Adaptive Behavior Composite Standard Score Minimum value = 20; Maximum value = 140; Higher scores indicate a better outcome
|
Baseline to Post-Intervention (12-14 weeks post baseline) Change
|
Adaptive Behavior
Time Frame: Baseline to Follow-Up (24-28 weeks post baseline) Change
|
Vineland Adaptive Behavior Scales - 3: Adaptive Behavior Composite Standard Score Minimum value = 20; Maximum value = 140; Higher scores indicate a better outcome
|
Baseline to Follow-Up (24-28 weeks post baseline) Change
|
Parenting Stress
Time Frame: Baseline to Post-Intervention (12-14 weeks post baseline) Change
|
Parenting Stress Index - Short Form Total Stress T Score Minimum value = 32; Maximum value = 92; Higher scores indicate a worse outcome
|
Baseline to Post-Intervention (12-14 weeks post baseline) Change
|
Parenting Stress
Time Frame: Baseline to Follow-Up (24-28 weeks post baseline) Change
|
Parenting Stress Index - Short Form Total Stress T Score Minimum value = 32; Maximum value = 92; Higher scores indicate a worse outcome
|
Baseline to Follow-Up (24-28 weeks post baseline) Change
|
Parent Empowerment
Time Frame: Baseline to Post-Intervention (12-14 weeks post baseline) Change
|
Family Outcomes Scales - Revised Minimum value = 1; Maximum value = 5; Higher scores indicate a better outcome
|
Baseline to Post-Intervention (12-14 weeks post baseline) Change
|
Parent Empowerment
Time Frame: Baseline to Follow-Up (24-28 weeks post baseline) Change
|
Family Outcomes Scales - Revised Minimum value = 1; Maximum value = 5; Higher scores indicate a better outcome
|
Baseline to Follow-Up (24-28 weeks post baseline) Change
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Child Challenging Behavior
Time Frame: Baseline to Post-Intervention (12-14 weeks post baseline) Change
|
Scales of Independent Behavior-Revised: Problem Behavior Subscale Minimum value = +10; Maximum value = -74; Higher scores indicate a better outcome
|
Baseline to Post-Intervention (12-14 weeks post baseline) Change
|
Child Challenging Behavior
Time Frame: Baseline to Follow-Up (24-28 weeks post baseline) Change
|
Minimum value = +10; Maximum value = -74; Higher scores indicate a better outcome
|
Baseline to Follow-Up (24-28 weeks post baseline) Change
|
Family Quality of Life
Time Frame: Baseline to Post-Intervention (12-14 weeks post baseline) Change
|
PedsQL Family Impact Module: Family Functioning Minimum value = 0; Maximum value = 100; Higher scores indicate a better outcome
|
Baseline to Post-Intervention (12-14 weeks post baseline) Change
|
Family Quality of Life
Time Frame: Baseline to Follow-Up (24-28 weeks post baseline) Change
|
PedsQL Family Impact Module: Family Functioning Minimum value = 0; Maximum value = 100; Higher scores indicate a better outcome
|
Baseline to Follow-Up (24-28 weeks post baseline) Change
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Sandra B Vanegas, PhD, Texas State University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 7, 2020
Primary Completion (ANTICIPATED)
June 30, 2022
Study Completion (ANTICIPATED)
June 30, 2022
Study Registration Dates
First Submitted
July 18, 2020
First Submitted That Met QC Criteria
August 5, 2020
First Posted (ACTUAL)
August 10, 2020
Study Record Updates
Last Update Posted (ACTUAL)
May 24, 2022
Last Update Submitted That Met QC Criteria
May 17, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 90IFST0004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Sharing Time Frame
Data will be available 1 year after study completion.
IPD Sharing Access Criteria
Electronic data from assessments will be submitted to Inter-university Consortium for Political and Social Research within 1 year after study completion for archival and storage purposes.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autism Spectrum Disorder
-
Stanford UniversityCalifornia Department of Developmental ServicesRecruitingAutism Spectrum Disorder | Autistic Disorder | Autism | Autism Spectrum Disorders | Autistic Disorders Spectrum | Autistic Spectrum Disorder | Autistic Spectrum DisordersUnited States
-
Hoffmann-La RocheActive, not recruitingAutism Spectrum Disorder (ASD)United States, Canada, Italy, Spain
-
Axial Therapeutics, Inc.Active, not recruitingAutism Spectrum Disorder (ASD)United States, Australia, New Zealand
-
Technion, Israel Institute of TechnologyCompleted
-
Stanford UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedAutism | Autism Spectrum Disorder (ASD)United States
-
Corporacion Parc TauliUnknown
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyTerminatedAutism Spectrum Disorder (ASD)Spain, United States, Hungary, Poland, Australia, United Kingdom, Brazil, Czechia, France, Italy, Portugal, Slovakia
-
Florida Gulf Coast UniversityCompletedAutism Spectrum Disorder High-FunctioningUnited States
-
Hospital Universitario Dr. Jose E. GonzalezUnknownAutism | Autism SpectrumMexico
-
AbbVieRecruitingSchizophrenia | Bipolar I Disorder | Autism Spectrum Disorder (ASD)United States, Puerto Rico
Clinical Trials on ASD Screening Parent ENgagement Intervention Program (ASPEN)
-
University of Massachusetts, BostonNational Institute of Mental Health (NIMH); Tufts Medical Center; Northeastern...Completed
-
Seoul National University HospitalCompletedAutism Spectrum Disorder | Autism
-
Sabri HergünerCompletedAutism Spectrum DisorderTurkey
-
National Taiwan University HospitalCompletedAutism Spectrum DisorderTaiwan
-
Sabri HergünerNot yet recruitingAutism Spectrum Disorder | Behavior Problem of Childhood and Adolescence | EarthquakeTurkey
-
Jessica BrianIWK Health CentreCompletedAutism Spectrum DisorderCanada
-
Erasmus Medical CenterUnknown
-
Seoul National University HospitalUnknownAutism Spectrum DisordersKorea, Republic of
-
University of FloridaNational Institute on Drug Abuse (NIDA)Withdrawn
-
Fundació Sant Joan de DéuHospital Universitari Vall d'Hebron Research Institute; Fundació La Marató... and other collaboratorsRecruitingParenting | Genetic Syndrome | Language Development | Autism or Autistic TraitsSpain